Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Shattuck Labs Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
STTK
Nasdaq
8731
https://www.shattucklabs.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Shattuck Labs Inc
Shattuck Labs Full Year 2023 Earnings: Beats Expectations
- Mar 5th, 2024 6:40 pm
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
- Mar 4th, 2024 12:00 pm
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
- Feb 29th, 2024 9:05 pm
Shattuck Labs Announces Participation in Upcoming March Conferences
- Feb 26th, 2024 12:00 pm
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
- Feb 14th, 2024 10:06 am
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
- Feb 13th, 2024 11:00 am
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
- Jan 8th, 2024 12:00 pm
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 9:05 pm
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
- Dec 21st, 2023 1:00 pm
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
- Dec 21st, 2023 10:14 am
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Dec 13th, 2023 11:00 am
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023
- Dec 5th, 2023 9:15 pm
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
- Nov 14th, 2023 2:00 pm
Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript
- Nov 13th, 2023 1:52 pm
Institutions profited after Shattuck Labs, Inc.'s (NASDAQ:STTK) market cap rose US$7.6m last week but individual investors profited the most
- Nov 10th, 2023 11:04 am
Q3 2023 Shattuck Labs Inc Earnings Call
- Nov 10th, 2023 4:54 am
Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates
- Nov 9th, 2023 1:29 pm
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Nov 9th, 2023 11:00 am
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
- Nov 6th, 2023 2:28 pm
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
- Nov 2nd, 2023 1:01 pm
Scroll